{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:49:07Z","timestamp":1792442947839,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.autrev.2021.102784","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:48:12Z","timestamp":1613609292000},"page":"102784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: A narrative review"],"prefix":"10.1016","volume":"20","author":[{"given":"Edoardo","family":"Conticini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Falsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Miracco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2021.102784_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102784_bb0010","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaut.2014.01.029","article-title":"Diagnosis and classification of polyarteritis nodosa","volume":"48-49","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2014","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0015","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.autrev.2016.02.015","article-title":"Polyarteritis nodosa: a contemporary overview","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2016.02.010","article-title":"Epidemiological, clinical and laboratory profiles of cutaneous polyarteritis nodosa patients: report of 22 cases and literature review","volume":"15","author":"Criado","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0025","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4103\/IJPM.IJPM_569_17","article-title":"Orchitis: an unusual presentation of polyarteritis nodosa","volume":"61","author":"Islam","year":"2018","journal-title":"Indian J Pathol Microbiol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102784_bb0030","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.autrev.2016.05.002","article-title":"Comment on \u201cPolyarteritis nodosa: a contemporary overview\u201d","volume":"15","author":"Toz","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2021.102784_bb0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.autrev.2016.06.002","article-title":"Reply to comment on \u201cPolyarteritis nodosa: a contemporary overview\u201d","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102784_bb0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.crad.2015.11.004","article-title":"Role of multidetector abdominal CT in the evaluation of abnormalities in polyarteritis nodosa","volume":"71","author":"Singhal","year":"2016","journal-title":"Clin Radiol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2021.102784_bb0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/1756-185X.13390","article-title":"Imaging in small and medium vessel vasculitis","volume":"22","author":"Singhal","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2021.102784_bb0050","first-page":"22","article-title":"Polyarteritis nodosa and microscopic polyangiitis. Clin Exp Immunol. 1995;101","volume":"1","author":"Guillevin","year":"1995","journal-title":"Suppl"},{"issue":"8","key":"10.1016\/j.autrev.2021.102784_bb0055","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/art.1780330805","article-title":"The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa","volume":"33","author":"Lightfoot","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2021.102784_bb0060","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00296-020-04535-2","article-title":"Provisional seven-item criteria for the diagnosis of polyarteritis nodosa","volume":"40","author":"Yamamoto","year":"2020","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.autrev.2021.102784_bb0065","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.autrev.2018.08.001","article-title":"Childhood- versus adult-onset Polyarteritis Nodosa results from the French Vasculitis study group registry","volume":"17","author":"Iudici","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2021.102784_bb0070","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria","volume":"69","author":"Ozen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102784_bb0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fped.2018.00377","article-title":"Vasculitis in systemic autoinflammatory diseases","volume":"6","author":"Demir","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.autrev.2021.102784_bb0080","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fimmu.2019.00763","article-title":"Association of Vasculitis and Familial Mediterranean Fever","volume":"10","author":"Abbara","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102784_bb0085","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJMoa1307362","article-title":"Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy","volume":"370","author":"Navon Elkan","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2021.102784_bb0090","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1307361","article-title":"Early-onset stroke and vasculopathy associated with mutations in ADA2","volume":"370","author":"Zhou","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0095","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.berh.2019.04.001","article-title":"Management of hepatitis B and C infections in rheumatologic disease","volume":"32","author":"Cheah","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0100","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients","volume":"62","author":"Ribi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2021.102784_bb0105","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/13543784.10.7.1279","article-title":"Novel therapies in vasculitis","volume":"10","author":"Thomas-Golbanov","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.autrev.2021.102784_bb0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.autrev.2013.10.001","article-title":"Guillevin L; French Vasculitis study group (FVSG). Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors","volume":"13","author":"Samson","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2021.102784_bb0115","first-page":"3","article-title":"One year in review 2020: vasculitis","volume":"124","author":"Felicetti","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 32","key":"10.1016\/j.autrev.2021.102784_bb0120","first-page":"S138","article-title":"Successful response to infliximab in a patient with undifferentiated spondyloarthropathy coexisting with polyarteritis nodosa-like cutaneous vasculitis","volume":"21","author":"Garcia-Porrua","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102784_bb0125","first-page":"1371","article-title":"Refractory polyarteritis nodosa successfully treated with infliximab","volume":"32","author":"Al-Bishri","year":"2005","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0130","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfk082","article-title":"A new treatment for polyarteritis nodosa","volume":"21","author":"Wu","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.autrev.2021.102784_bb0135","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-005-0071-7","article-title":"Infliximab in a child with therapy-resistant systemic vasculitis","volume":"25","author":"de Kort","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0140","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1468-3083.2006.01967.x","article-title":"Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab","volume":"21","author":"Vega Gutierrez","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102784_bb0145","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s10067-006-0521-x","article-title":"Tumor necrosis factor blockade in the management of children with orphan diseases","volume":"26","author":"Brik","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102784_bb0150","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","article-title":"Biologic therapy in primary systemic vasculitis of the young","volume":"48","author":"Eleftheriou","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102784_bb0155","doi-asserted-by":"crossref","first-page":"687547","DOI":"10.1155\/2010\/687547","article-title":"Cutaneous polyarteritis nodosa in childhood: a case report and review of the literature","volume":"2010","author":"Bansal","year":"2010","journal-title":"Arthritis."},{"issue":"3","key":"10.1016\/j.autrev.2021.102784_bb0160","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1542\/peds.2009-3331","article-title":"Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment","volume":"126","author":"Wahezi","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.autrev.2021.102784_bb0165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jbspin.2013.11.009","article-title":"Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immunosuppression and rituximab","volume":"81","author":"Campanilho-Marques","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"11","key":"10.1016\/j.autrev.2021.102784_bb0170","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2169\/internalmedicine.56.8235","article-title":"The successful treatment of refractory Polyarteritis Nodosa using infliximab","volume":"56","author":"Matsuo","year":"2017","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.autrev.2021.102784_bb0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ad.2017.01.021","article-title":"Polyarteritis Nodosa with a systemic inflammatory response pattern: effectiveness of anti-TNF. Panarteritis nudosa con patr\u00f3n de respuesta inflamatoria sist\u00e9mica: respuesta a anti-TNF","volume":"108","author":"Tous-Romero","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0180","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/pde.14005","article-title":"Cutaneous polyarteritis nodosa in pediatric patients successfully treated with TNF-\u03b1 inhibitor and methotrexate: case series and literature review","volume":"36","author":"Do","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2021.102784_bb0185","first-page":"111","article-title":"Recurrent ruptured abdominal aneurysms in polyarteritis nodosa successfully treated with infliximab","volume":"13","author":"Lerkvaleekul","year":"2019","journal-title":"Biologics"},{"issue":"10","key":"10.1016\/j.autrev.2021.102784_bb0190","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s10067-019-04474-9","article-title":"Infliximab for the treatment of refractory polyarteritis nodosa","volume":"38","author":"Ginsberg","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0195","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/ped.14184","article-title":"Successful treatment of tumor necrosis factor inhibitor-resistant cutaneous polyarteritis nodosa with tocilizumab","volume":"62","author":"Inoue","year":"2020","journal-title":"Pediatr Int"},{"issue":"1","key":"10.1016\/j.autrev.2021.102784_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000446","article-title":"Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?","volume":"3","author":"Saunier","year":"2017","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.rhu.0000173225.41933.83","article-title":"Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade","volume":"11","author":"Feinstein","year":"2005","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0210","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3109\/14397595.2013.874737","article-title":"Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept","volume":"24","author":"Valor","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102784_bb0215","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fphar.2014.00122","article-title":"Etanercept induces remission of polyarteritis nodosa: a case report","volume":"5","author":"Capuozzo","year":"2014","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102784_bb0220","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3109\/s10165-012-0732-8","article-title":"A case of refractory cutaneous polyarteritis nodosa in a patient with hepatitis B carrier status successfully treated with tumor necrosis factor alpha blockade","volume":"23","author":"Zoshima","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2021.102784_bb0225","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/annrheumdis-2016-209330","article-title":"Tofacitinib for polyarteritis nodosa: a tailored therapy","volume":"75","author":"Rimar","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"10.1016\/j.autrev.2021.102784_bb0230","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011053","article-title":"Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: a case report","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/13506129.2013.838947","article-title":"AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab","volume":"20","author":"Ho\u010devar","year":"2013","journal-title":"Amyloid."},{"key":"10.1016\/j.autrev.2021.102784_bb0240","first-page":"7987081","article-title":"A case of Polyarteritis Nodosa associated with vertebral artery Vasculitis treated successfully with tocilizumab and cyclophosphamide","volume":"2016","author":"Watanabe","year":"2016","journal-title":"Case Rep Pediatr"},{"issue":"8","key":"10.1016\/j.autrev.2021.102784_bb0245","first-page":"560","article-title":"Tocilizumab treatment in Polyarteritis Nodosa","volume":"21","author":"Bodoki","year":"2019","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2021.102784_bb0250","article-title":"Tocilizumab treatment for polyarteritis nodosa [published online ahead of print, 2020 Mar 17]","volume":"2020","author":"Krusche","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2021.102784_bb0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2177\/jsci.31.119","volume":"31","author":"Sonomoto","year":"2008","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"8","key":"10.1016\/j.autrev.2021.102784_bb0260","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/RHU.0b013e31823a58d7","article-title":"Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab","volume":"17","author":"N\u00e9el","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0265","first-page":"531","article-title":"Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review","volume":"55","author":"da Silva","year":"2015","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.autrev.2021.102784_bb0270","doi-asserted-by":"crossref","first-page":"738293","DOI":"10.1155\/2009\/738293","article-title":"Rituximab efficacy during a refractory Polyarteritis Nodosa flare","volume":"2009","author":"Ribeiro","year":"2009","journal-title":"Case Rep Med"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0275","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3109\/14397595.2015.1014153","article-title":"A case of refractory polyarteritis nodosa successfully treated with rituximab","volume":"27","author":"Seri","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102784_bb0280","doi-asserted-by":"crossref","DOI":"10.1111\/j.1756-185X.2012.01733.x","article-title":"Rituximab in refractory cutaneous polyarteritis","volume":"15","author":"Krishnan","year":"2012","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2021.102784_bb0285","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s10067-011-1756-8","article-title":"Long-term follow-up of different refractory systemic vasculitides treated with rituximab","volume":"30","author":"Rees","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102784_bb0290","article-title":"Two cases of ADA2 deficiency presenting as childhood polyarteritis nodosa: novel ADA2 variant, atypical CNS manifestations, and literature review [published online ahead of print, 2020 Jun 13]","volume":"2020","author":"Ganh\u00e3o","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102784_bb0295","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-017-0699-8","article-title":"Deficiency of adenosine deaminase 2 (DADA2), an inherited cause of Polyarteritis Nodosa and a mimic of other systemic rheumatologic disorders","volume":"19","author":"Hashem","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2021.102784_bb0300","series-title":"GeneReviews\u00ae","article-title":"Adenosine deaminase 2 deficiency","author":"Aksentijevich","year":"1993"},{"issue":"8","key":"10.1016\/j.autrev.2021.102784_bb0305","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3899\/jrheum.150024","article-title":"A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations","volume":"42","author":"Batu","year":"2015","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102784_bb0310","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/kev439","article-title":"Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations","volume":"55","author":"Van Montfrans","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0315","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/08880018.2019.1621973","article-title":"A homozygote novel L451W mutation in CECR1 gene causes deficiency of adenosine deaminase 2 in a pediatric patient representing with chronic lymphoproliferation and cytopenia","volume":"36","author":"Ekinci","year":"2019","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.autrev.2021.102784_bb0320","article-title":"Treatment of two male children suffering from deficiency of adenosine deaminase type 2 (DADA2) with TNF-inhibitor Etanercept [published online ahead of print, 2019 Oct 22]","volume":"2019","author":"Krutzke","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102784_bb0325","doi-asserted-by":"crossref","first-page":"413","DOI":"10.24953\/turkjped.2019.03.014","article-title":"Atypical phenotype of an old disease or typical phenotype of a new disease: deficiency of adenosine deaminase 2","volume":"61","author":"\u00c7akan","year":"2019","journal-title":"Turk J Pediatr"},{"issue":"10","key":"10.1016\/j.autrev.2021.102784_bb0330","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/annrheumdis-2016-210802","article-title":"ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study [published correction appears in Ann Rheum Dis. 2019 Jul;78(7):e73]","volume":"76","author":"Caorsi","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.autrev.2021.102784_bb0335","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1056\/NEJMc1801927","article-title":"Treatment strategies for deficiency of adenosine deaminase 2","volume":"380","author":"Ombrello","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.autrev.2021.102784_bb0340","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2017-07-798660","article-title":"Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2","volume":"130","author":"Hashem","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.autrev.2021.102784_bb0345","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10875-018-0487-x","article-title":"Novel mutation in CECR1 leads to deficiency of ADA2 with associated neutropenia","volume":"38","author":"Cipe","year":"2018","journal-title":"J Clin Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102784_bb0350","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/art.39699","article-title":"Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases","volume":"68","author":"Nanthapisal","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102784_bb0355","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12969-019-0334-5","article-title":"Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2)","volume":"17","author":"Clarke","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.autrev.2021.102784_bb0360","first-page":"480","article-title":"Mutant ADA2 in vasculopathies","volume":"371","author":"Van Eyck","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2021.102784_bb0365","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-2266","article-title":"ADA2 deficiency mimicking idiopathic multicentric Castleman disease","volume":"142","author":"Van Nieuwenhove","year":"2018","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.autrev.2021.102784_bb0370","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00251-018-01101-w","article-title":"A Chinese DADA2 patient: report of two novel mutations and successful HSCT","volume":"71","author":"Liu","year":"2019","journal-title":"Immunogenetics"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0375","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00431-014-2320-8","article-title":"Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy","volume":"173","author":"Garg","year":"2014","journal-title":"Eur J Pediatr"},{"issue":"5","key":"10.1016\/j.autrev.2021.102784_bb0380","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0948","article-title":"Renal amyloidosis in deficiency of adenosine deaminase 2: successful experience with Canakinumab","volume":"142","author":"Kisla Ekinci","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.autrev.2021.102784_bb0385","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1546-0096-12-44","article-title":"Mutations in CECR1 associated with a neutrophil signature in peripheral blood","volume":"12","author":"Belot","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.autrev.2021.102784_bb0390","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2249.1990.tb03336.x","article-title":"Enhanced expression of the tumour necrosis factor\/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis","volume":"81","author":"Deguchi","year":"1990","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102784_bb0395","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2340\/00015555-1228","article-title":"Serum levels of interleukin-6 in patients with cutaneous polyarteritis nodosa","volume":"92","author":"Kawakami","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102784_bb0400","first-page":"196","article-title":"Serum cytokine changes in systemic vasculitis","volume":"68","author":"Grau","year":"1989","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.12.908","article-title":"Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)","volume":"145","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102784_bb0410","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jaci.2020.04.023","article-title":"Deficiency of adenosine deaminase 2: is it an elephant after all?","volume":"145","author":"Schnappauf","year":"2020","journal-title":"J Allergy Clin Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:44Z","timestamp":1761600164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1568997221000471"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102784","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102784"}}